GB201516243D0 - Novel compounds - Google Patents
Novel compoundsInfo
- Publication number
- GB201516243D0 GB201516243D0 GBGB1516243.1A GB201516243A GB201516243D0 GB 201516243 D0 GB201516243 D0 GB 201516243D0 GB 201516243 A GB201516243 A GB 201516243A GB 201516243 D0 GB201516243 D0 GB 201516243D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- novel compounds
- novel
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1516243.1A GB201516243D0 (en) | 2015-09-14 | 2015-09-14 | Novel compounds |
| PCT/EP2016/071466 WO2017046036A1 (en) | 2015-09-14 | 2016-09-12 | Compounds for the modulation of rip2 kinase activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1516243.1A GB201516243D0 (en) | 2015-09-14 | 2015-09-14 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201516243D0 true GB201516243D0 (en) | 2015-10-28 |
Family
ID=54363130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1516243.1A Ceased GB201516243D0 (en) | 2015-09-14 | 2015-09-14 | Novel compounds |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB201516243D0 (en) |
| WO (1) | WO2017046036A1 (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017019751A2 (en) | 2015-03-18 | 2018-05-29 | Arvinas Inc | bifunctional compound, pharmaceutical composition, and methods for treating or preventing a disease or disorder, and for degrading a target protein in a cell |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| US10532103B2 (en) * | 2016-04-22 | 2020-01-14 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 9 (CDK9) by conjugation of CDK9 inhibitors with E3 ligase ligand and methods of use |
| CN110234646A (en) | 2016-11-01 | 2019-09-13 | 阿尔维纳斯股份有限公司 | Target the Tau albumen and associated method of use of PROTAC |
| LT3689868T (en) | 2016-12-01 | 2023-12-27 | Arvinas Operations, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| WO2018118598A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US10994015B2 (en) | 2016-12-23 | 2021-05-04 | Arvinas Operations, Inc. | EGFR proteolysis targeting chimeric molecules and associated methods of use |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| BR112019012878A2 (en) | 2016-12-23 | 2019-11-26 | Arvinas Operations Inc | compounds and methods for target degradation of rapidly accelerated fibrosarcoma polypeptides |
| WO2018140809A1 (en) | 2017-01-26 | 2018-08-02 | Arvinas, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| CN111372585A (en) | 2017-11-16 | 2020-07-03 | C4医药公司 | Degradants and degreddeterminants for target protein degradation |
| WO2019099926A1 (en) | 2017-11-17 | 2019-05-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| JP2021527137A (en) * | 2018-06-13 | 2021-10-11 | アンフィスタ セラピューティクス リミテッド | Bifunctional molecule for targeting Rpn11 |
| EP3841100A1 (en) | 2018-08-20 | 2021-06-30 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
| WO2020043122A1 (en) * | 2018-08-28 | 2020-03-05 | 南京明德新药研发有限公司 | Quinazoline derivatives as rip2 kinase inhibitor |
| CA3119773A1 (en) * | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| US20230045737A1 (en) * | 2018-12-05 | 2023-02-09 | Vividion Therapeutics, Inc. | Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | Targeted protein degradation |
| WO2020191369A1 (en) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| KR20210141554A (en) | 2019-03-21 | 2021-11-23 | 코디악 바이오사이언시즈, 인크. | Extracellular vesicle conjugates and uses thereof |
| CN114867727A (en) * | 2019-07-17 | 2022-08-05 | 阿尔维纳斯运营股份有限公司 | TAU protein targeting compounds and related methods of use |
| AU2020387392A1 (en) | 2019-11-19 | 2022-07-14 | Bristol-Myers Squibb Company | Compounds useful as inhibitors of Helios protein |
| WO2021127443A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CN111499623B (en) * | 2020-04-01 | 2022-07-08 | 南京缘聚医药科技有限公司 | Thiazolone urea derivatives of non-nucleoside antitumor drugs and pharmaceutical application thereof |
| WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| WO2022066928A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| WO2022120118A1 (en) * | 2020-12-03 | 2022-06-09 | Baylor College Of Medicine | Novel ripk1 kinase targeting protacs and methods of use thereof |
| AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| BR112023020077A2 (en) | 2021-04-06 | 2023-11-14 | Bristol Myers Squibb Co | OXOISOINDOLINE COMPOUNDS REPLACED BY PYRIDINYL |
| EP4333899A1 (en) | 2021-05-05 | 2024-03-13 | Biogen MA Inc. | Compounds for targeting degradation of bruton's tyrosine kinase |
| EP4355741A1 (en) * | 2021-06-16 | 2024-04-24 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2023283372A1 (en) | 2021-07-07 | 2023-01-12 | Biogen Ma Inc. | Compounds for targeting degradation of irak4 proteins |
| CA3224732A1 (en) | 2021-07-07 | 2023-01-12 | Kevin M. Guckian | Compounds for targeting degradation of irak4 proteins |
| US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0689424B1 (en) | 1993-03-17 | 1998-10-14 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid |
| US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
| JP4641526B2 (en) | 2003-11-03 | 2011-03-02 | グラクソ グループ リミテッド | Fluid distribution device |
| GB0610666D0 (en) | 2006-05-30 | 2006-07-05 | Glaxo Group Ltd | Fluid dispenser |
| WO2011140442A1 (en) | 2010-05-07 | 2011-11-10 | Glaxo Group Limited | Amino-quinolines as kinase inhibitors |
| UY33549A (en) | 2010-08-10 | 2012-01-31 | Glaxo Group Ltd | QUINOLIL AMINAS AS INHIBITING AGENTS OF KINASES |
| CA2829131C (en) | 2011-03-04 | 2018-11-20 | Glaxosmithkline Intellectual Property (No.2) Limited | Amino-quinolines as kinase inhibitors |
| TWI547494B (en) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | Amino quinazolines as kinase inhibitors |
| EP2802608A4 (en) | 2012-01-12 | 2015-08-05 | Univ Yale | Compounds&methods for the enhanced degradation of targeted proteins&other polypeptides by an e3 ubiquitin ligase |
| AR092530A1 (en) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | AMINO-QUINOLINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THIS COMPOUND FOR THE PREPARATION OF A MEDICINAL PRODUCT |
| KR20150118152A (en) | 2013-02-21 | 2015-10-21 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Quinazolines as kinase inhibitors |
-
2015
- 2015-09-14 GB GBGB1516243.1A patent/GB201516243D0/en not_active Ceased
-
2016
- 2016-09-12 WO PCT/EP2016/071466 patent/WO2017046036A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017046036A1 (en) | 2017-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1256059A1 (en) | Novel compounds | |
| HK1243410A1 (en) | Novel compounds | |
| GB201521109D0 (en) | Novel compounds | |
| GB201516243D0 (en) | Novel compounds | |
| GB201522768D0 (en) | Novel compounds | |
| GB201506871D0 (en) | Novel compounds | |
| GB201501462D0 (en) | Novel compounds | |
| GB201510019D0 (en) | Compounds | |
| GB201522179D0 (en) | Novel compounds | |
| GB201514754D0 (en) | Compounds | |
| GB201514751D0 (en) | Compounds | |
| GB201504565D0 (en) | Novel compounds | |
| GB201508747D0 (en) | Compounds | |
| GB201508864D0 (en) | Compounds | |
| GB201510493D0 (en) | Compounds | |
| GB201502675D0 (en) | Novel compounds | |
| GB201508857D0 (en) | Compounds | |
| GB201503926D0 (en) | Compounds | |
| GB201501115D0 (en) | Compounds | |
| GB201521749D0 (en) | Novel compounds | |
| GB201521713D0 (en) | Novel compounds | |
| GB201516241D0 (en) | Novel compounds | |
| GB201512829D0 (en) | Novel compounds | |
| GB201512270D0 (en) | Novel Compounds | |
| GB201511842D0 (en) | Novel compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |